Features
AlgenCRISPR next-generation gene-modulation system
Fine-tuned and precise gene editing capability
AlgenBrain AI platform with deep learning models
Predicts RNA signaling networks from gene expression
Processes billions of real-time dynamic gene expression changes
Industrial-scale single-cell gene modulation
Reverse engineers disease trajectory for causal biology
High-confidence therapeutic target discovery
Human-centric drug discovery endpoints
Partnerships with pharmaceutical companies like AstraZeneca
Built on discoveries from Nobel Laureate Jennifer Doudna's lab
Proprietary Recursion OS platform for drug discovery
Automated wet lab generating millions of cell experiments per week
Over 50 petabytes of biological and chemical data
NVIDIA BioHive-2 supercomputer for AI model training
Hit identification to IND-enabling studies with improved speed and cost
Potential first-in-class treatments in oncology and rare diseases
Advanced pipeline with phase 1/2/3 clinical trials (REC-4881, REC-3565)
Target identification and validation using machine learning
Generative AI for molecule design and optimization
De-identified patient data integration for precision medicine
Strategic partnerships with pharma and tech leaders
End-to-end drug development capability from preclinical to pivotal studies
Fit-for-purpose dataset generation including ADME and safety profiling
Real-world evidence generation through clinical trials
Continuous feedback loop from experiments into AI models
